Toggle navigation
Logout
Change account settings
EN
DE
ES
FR
A-Z
Beta
About EconBiz
News
Thesaurus (STW)
Research Skills
Help
EN
DE
ES
FR
My account
Logout
Change account settings
Login
Publications
Events
Your search terms
Search
Search options
All Fields
Title
Exact title
Subject
Author
Institution
ISBN/ISSN
Published in...
Publisher
Open Access only
Advanced
Search history
My EconBiz
Favorites
Loans
Reservations
Fines
You are here:
Home
Search: subject:"Ruxolitinib"
Narrow search
Narrow search
Year of publication
From:
To:
Subject
All
Access to Medicines
4
Affordable Medicines
4
Biotherapeutics
4
COVID-19
4
Coronavirus
4
Favipiravir
4
Global Health
4
Health
4
Intellectual Property
4
Pandemic
4
Patent
4
Public Health
4
Remdesivir
4
Ruxolitinib
4
Sarilumab
4
Siltuximab
4
Tocilizumab
4
Arzneimittel
2
European Union (EU)
2
France
2
Gesundheitspolitik
2
Gesundheitsversorgung
2
Gesundheitswesen
2
Health care
2
Health care system
2
Health policy
2
Immaterialgüterrechte
2
Impact assessment
2
India
2
Intellectual property rights
2
Medical sciences
2
Medizin
2
Molnupiravir
2
Nirmatrelvir
2
Patent Offices
2
Patent law
2
Patentrecht
2
Pharmaceuticals
2
TRIPS
2
United Nations Development Programme (UNDP)
2
more ...
less ...
Online availability
All
Free
4
Type of publication
All
Book / Working Paper
4
Type of publication (narrower categories)
All
Arbeitspapier
2
Graue Literatur
2
Non-commercial literature
2
Research Report
2
Working Paper
2
Language
All
English
4
Author
All
Ravi, Srividya
4
Published in...
All
Research Paper
2
Research paper
2
Source
All
ECONIS (ZBW)
2
EconStor
2
Showing
1
-
4
of
4
Sort
relevance
articles prioritized
date (newest first)
date (oldest first)
1
Patent analysis for medicines and biotherapeutics in trials to treat COVID-19
Ravi, Srividya
-
2022
patent analysis in this report are remdesivir,
ruxolitinib
, favipiravir, molnupiravir and nirmatrelvir, and the …
Persistent link: https://www.econbiz.de/10013330854
Saved in:
2
Patent analysis for medicines and biotherapeutics in trials to treat COVID-19
Ravi, Srividya
-
2022
patent analysis in this report are remdesivir,
ruxolitinib
, favipiravir, molnupiravir and nirmatrelvir, and the …
Persistent link: https://www.econbiz.de/10013194325
Saved in:
3
Patent analysis for medicines and biotherapeutics in trials to treat COVID-19
Ravi, Srividya
-
2020
patent analysis in this report are remdesivir,
ruxolitinib
and favipiravir, and the biotherapeutics tocilizumab, siltuximab …
Persistent link: https://www.econbiz.de/10012490900
Saved in:
4
Patent analysis for medicines and biotherapeutics in trials to treat COVID-19
Ravi, Srividya
-
2020
Persistent link: https://www.econbiz.de/10012433647
Saved in:
Results per page
10
25
50
100
250
A service of the
zbw
×
Loading...
